GLP2-T

IMPORTANT: Read This Before Proceeding With Dosing
Go to the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.

Click here to read the Prep & Injection Guide

GLP2-T was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.

Unlike its predecessor (which only targets GLP-1), GLP2-T showed 5–7% more weight loss in clinical trials. Compared to GLP3-R, a triple agonist, GLP2-T accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48).

MECHANISM OF ACTION

• GLP-1: Suppresses appetite and increases feelings of fullness after eating.
• GIP: Promotes insulin secretion and supports energy balance through receptors in the hypothalamus.

BENEFITS

• Average weight loss of 24.7% after 72 weeks
• Reduces appetite and cravings
• Enhances satiety and energy balance
• Supports fat oxidation and metabolism
• Improves insulin sensitivity and blood sugar control

POSSIBLE SIDE EFFECTS (often mild and temporary; affected only ~25% in trials)

• Injection site reaction (redness, swelling, itching)
• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Fatigue
• Dyspepsia (indigestion)
• Abdominal pain
• Burping (may have sulfur smell)
• Hair loss

RARE BUT SERIOUS RISKS

• Thyroid C-Cell Tumors
• Pancreatitis
• Gastroparesis (stomach paralysis)
• Hypoglycemia (if used with insulin)
• Gallbladder disease
• Kidney issues (linked to dehydration)
• Pulmonary aspiration under anesthesia – ALWAYS disclose GLP2-T use to surgical teams

INTERACTIONS

• Insulin and Insulin-stimulating drugs: includes all forms of insulin, sulfonylureas (glipizide, glyburide, glimepiride), and glinides (repaglinide), due to the increased risk of hypglycemia
• Oral medications: GLP2-T may interfere the absorption of oral medications
• Oral birth control medications: increases the likelihood of additive GI effects, may lead to excessive appetite suppression, and increases the risk of hypoglycemia
• Growth hormone/GH analogs: interactions have been reported with Somatropin, Lonapegsomatropin, Somapacitan
• Alcohol: increases the risk of hypoglycemia and worsens nausea and dehydration
• Dehydration risk: dehydration places excessive stress on the kidneys, and may lead to kidney damage; this risk increases with concurrent use with ACE inhibitors, diuretics, ARB’s, and heart failure regimens
• Berberine/Metformin: increased risk of hypoglycemia
• Chromium/Insulin Sensitizers: increased risk of hypoglycemia
• Appetite suppressants: added risk of eating disorder/anorexia
• Stimulants: excessively diminished appetite and GI intolerance overlap
• Large, greasy meals: increases the likelihood of nausea

PEPTIDE INTERACTIONS

SEVERE

• Other GLP peptides: Receptor redundancy and desensitization
• Tesamorelin: Elevated glucose levels
• IGF-1 LR3/DES and strong ghrelin agonists (e.g. GHRP 2 and 6): may oppose or significantly amplifyGLP2–T’s metabolic signaling

MODERATE

• IGF-1 LR3 and IGF-1 DES: Risk of hypoglycemia and rapid glucose uptake
• CJC WITH DAC: Blunts GLP metabolic benefit
• GHRP-2, GHRP-6, Hexarelin: Can counter appetite suppression
• BAM-15: Watch appetite suppression and fatigue
• LL-37: May worsen nausea and inflammation
• Oxytocin: Monitor excessive appetite loss

CONTRAINDICATIONS

• Do not use if pregnant or breastfeeding
• Do not use with a personal or family history of Medullary Thyroid Carcinoma or MEN 2 (Multiple Endocrine Neoplasia)
• Do not use if you have Type-1 diabetes, diabetic retinopathy, or severe GI disease
• Do not use if you are allergic or hypersensitive to GLP2-T

If you have never taken ANY GLP:
Your starting dose is 2.5mg

*

If you have previously taken any GLP for at least one month at the standard starter/adaptive dose, no matter how much time has elapsed since:
Your starting dose is 5mg

RECONSTITUTION, DOSING, & RELATED INFO

GLP2-T: 10MG

RECONSTITUTION

Mix with 0.5mL (50 units) of BAC water

Dose once per week (every 7 days), always on the same day of the week

You must remain on each dose for a minimum of 4 weeks before moving to the next dose

May be taken at any time of day/night

It is not necessary to be in a fasted state to dose

2.5mg = 12 units

5 mg = 25 units

7.5mg = 36 units

10mg = 50 units

GLP2-T: 30MG

RECONSTITUTION

Mix with 1.5mL (150 units) of BAC water

Dose once per week (every 7 days), always on the same day of the week

You must remain on each dose for a minimum of 4 weeks before moving to the next dose

May be taken at any time of day/night

It is not necessary to be in a fasted state to dose

Subcutaneous Administration

2.5mg = 12 units

5 mg = 25 units

7.5mg = 36 units

10mg = 50 units

12.5mg = 62 units

15mg = 75 units

GLP2-T: 60MG

RECONSTITUTION

60MG Mix with 2.5mL (250 units) of BAC water

Dose once per week (every 7 days), always on the same day of the week

You must remain on each dose for a minimum of 4 weeks before moving to the next dose

May be taken at any time of day/night

It is not necessary to be in a fasted state to dose

Subcutaneous Administration

2.5mg = 10 units

5 mg = 21 units

7.5mg = 31 units

10mg = 42 units

12.5mg = 52 units

15mg = 62 units

STACKING SUGGESTIONS

• AOD-9604 – enhances fat breakdown and further accelerates weight loss alongside appetite suppression
• Tesamorelin – synergistic for fat reduction, especially visceral fat and metabolic regulation
• Semax or Selank – manage mood and cognitive function while adjusting to appetite changes
• NAD+ or MOTS-C – support energy, mitochondrial efficiency, and metabolism while on a caloric deficit
• BPC-157 – beneficial for gut repair if experiencing nausea, indigestion, or stomach discomfort
• CJC-1295 / Ipamorelin – for muscle maintenance and enhanced metabolic recovery while losing fat